UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run

UroGen Pharma's Chief Medical Officer Mark Schoenberg sold 10,000 shares worth $400,000 on July 9, 2026, under a pre-established Rule 10b5-1 trading plan adopted in August 2025. Despite the sale, Schoenberg retains 119,763 shares valued at $4.82 million. The transaction should not be viewed negatively as it was scheduled long in advance and the CMO maintains significant holdings. UroGen's Zusduri bladder cancer therapy is performing well with Q1 revenue jumping 152% to $51 million, and the company recently received FDA clearance for an investigational new drug application for UGN-501.